- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01841658
Folic Acid Supplementation in Women of Child Bearing Age (FASUPP)
Effect of Obesity and Folic Acid Supplementation on Gene-specific DNA Methylation in Women of Reproductive Age
The objective of this study is to identify genes whose expression is potentially modifiable due to changes in folate intake and help delineate mechanisms accounting for the variability in individual response to folic acid supplementation. The study will be conducted in normal weight and obese women of childbearing age, supplemented for 8 weeks with 800 mcg/day folic acid.
It is hypothesized that (1) a change in folate status, induced by the supplementation, will influence the DNA methylation of specific genes and (2) the DNA methylation response to folic acid supplementation may differ between the normal weight and the obese women of childbearing age.
Studieöversikt
Detaljerad beskrivning
This study will be conducted in two phases. An initial screening study will be performed to determine folate status, MTHFR677 genotype and body composition of potential participants of the intervention study. Both folate status and MTHFR677 genotype are known independent predictors of response to folic acid supplementation. Blood samples will be collected, after an overnight fast, for determination of serum folate concentration and for MTHFR677 genotyping. Body composition and 24-hr dietary recalls will also be conducted during the screening visit.
The second phase is an eight week supplementation trial with 800 mcg/day folic acid. Screened individuals determined to have a serum folate < 30 nmol/L (< 50th percentile of NHANES 1999-2004) and of the CC or CT genotype (for MTHFR677) will be eligible for inclusion in the supplementation trial. Participants will be instructed to avoid dietary supplements, fortified ready-to-eat cereals, and other high folate content foods during intervention. Blood samples will be collected, after an overnight fast, at baseline and after 4 and 8 weeks of supplementation for determination of primary (DNA methylation profile) and secondary (nutritional, metabolic and health status biomarkers) outcome measures.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Georgia
-
Athens, Georgia, Förenta staterna, 30602
- University of Georgia
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Screening Phase:
- Female 18-40 yr
- Body Mass index 18.5 to 24.9 or > 30 kg/m2
- Intervention Study:
- Serum folate < 30 nmol/L
- MTHFR677CC or MTHFR677CT genotype
Exclusion Criteria:
- Currently pregnant, pregnancy within past 12 months
- Greater than 2 previous pregnancies
- Use of prescription drugs other than oral contraceptives
- Chronic disease (diabetes, hypertension,epilepsy,cancer, kidney disease, CVD)
- Acute illness (pneumonia, urinary tract infection, mononucleosis)
- Use of antibiotics in past 30 days
- Current smoker
- Use of dietary supplements including multivitamins in past 30 days
- Habitual consumption of fortified ready-to-eat cereals
- Significant weight change in past 12 months
- Typical alcohol consumption of 2 or more drinks per day
- INTERVENTION: all above plus serum folate > 30 nmol/L; MTHFR677TT genotype
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Folic Acid Normal Weight
Folic acid, tablet, 800 mcg, daily, eight weeks.
Normal Weight individuals, each will serve as her own control.
|
Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid.
To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff.
Additionally, compliance will be determined by return pill count.
|
Experimentell: Folic acid Obese
Folic acid, tablet, 800 mcg, daily, eight weeks.
Obese individuals, each will serve as her own control.
|
Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid.
To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff.
Additionally, compliance will be determined by return pill count.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Cell-type-specific DNA methylation
Tidsram: Baseline, 4 weeks and 8 weeks
|
Change in DNA methylation in response to 4 or 8 weeks supplementation with 800 mcg/day of folic acid will be determined in DNA isolated from specific white blood cell types.
Microarray analysis will be used to assess changes in multiple methylation sites within regulatory pathways for folate metabolism and/or development.
Each subject will serve as her own control.
|
Baseline, 4 weeks and 8 weeks
|
Gene-specific DNA methylation
Tidsram: Baseline, 4 weeks and 8 weeks
|
Change in DNA methylation in response to 4 or 8 weeks supplementation with 800 mcg/day of folic acid will be determined in DNA isolated from whole blood .
Microarray analysis will be used to assess changes in multiple methylation sites of specific genes within regulatory pathways for folate metabolism and/or development.
Each subject will serve as her own control.
|
Baseline, 4 weeks and 8 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Serum folate
Tidsram: Baseline, 4 weeks and 8 weeks
|
Change in serum folate concentrations in response to 4 or 8 weeks supplementation with 800 mcg/day of folic acid will be determined by microbiological assay using Lactobacillus rhamnosus.
Each subject will serve as her own control.
|
Baseline, 4 weeks and 8 weeks
|
Red Blood Cell (RBC) Folate
Tidsram: Baseline, 4 weeks and 8 weeks
|
Change in red blood cell (RBC) folate in response to 4 or 8 weeks supplementation with 800 mcg/day of folic acid will be determined by microbiological assay using Lactobacillus rhamnosus.
|
Baseline, 4 weeks and 8 weeks
|
Body Composition
Tidsram: Baseline and 8 weeks
|
Body composition in terms of fat mass (g), lean mass (g) and % body fat will be determined using the BODPOD instrument and verified by dual-energy X-ray absorptiometry (DXA).
The DXA analysis will also provide an indication of regional fat distribution, and total bone area, bone mineral content and bone density.
|
Baseline and 8 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Lynn B Bailey, PhD, University of Georgia
- Studierektor: Dorothy Hausman, PhD, University of Georgia
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- UGA_FASUPPLEMENT_EPIGEN
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Fetma
-
SanionaAvslutadHypothalamic Injury-induced Obesity (HIO)Danmark
Kliniska prövningar på Folic acid
-
Xiyuan Hospital of China Academy of Chinese Medical...Guangdong Provincial Hospital of Traditional Chinese Medicine; Beijing... och andra samarbetspartnersRekrytering
-
The Hospital for Sick ChildrenDuchesnay Inc.Avslutad
-
University of MalayaRekryteringAnemi | Post partum blödningMalaysia
-
Ultragenyx Pharmaceutical IncAvslutadHereditary Inclusion Body Myopathy (HIBM)Förenta staterna
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteAvslutadBipolär depressionIrland
-
University of California, Los AngelesAvslutadGlukosintolerans | Fet | Pre-diabetesFörenta staterna
-
Becton, Dickinson and CompanyAktiv, inte rekryterande
-
Ultragenyx Pharmaceutical IncAvslutadÄrftlig inklusionskroppsmyopati | GNE Myopati | Inklusionskroppsmyopati 2 | Distal Myopati Med Kantade Vakuoler | Distal myopati, typ Nonaka | Quadriceps sparande myopatiKanada, Förenta staterna, Bulgarien
-
Ultragenyx Pharmaceutical IncAvslutadÄrftlig inklusionskroppsmyopati | GNE Myopati | Distal Myopati Med Kantade Vakuoler | Distal myopati, typ Nonaka | Quadriceps sparande myopatiFörenta staterna, Kanada, Storbritannien, Israel, Italien, Bulgarien, Frankrike
-
University of Colorado, DenverAvslutadFetma | Polycystiskt ovariesyndrom | Hepatisk SteatosFörenta staterna